The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.